A Phase 2a Double-blind, Placebo-controlled, Parallel Study of PH94B Nasal Spray in the Treatment of Adjustment Disorder With Anxiety
Latest Information Update: 13 Jul 2023
At a glance
- Drugs Fasedienol (Primary)
- Indications Adjustment disorders; Anxiety
- Focus Therapeutic Use
- Sponsors VistaGen Therapeutics
Most Recent Events
- 07 Feb 2023 Status changed from recruiting to completed, according to a VistaGen Therapeutics media release.
- 10 Jan 2023 According to a VistaGen Therapeutic media release, data analysis will be completed over the coming months.
- 10 Jan 2023 According to a VistaGen Therapeutic media release, last patient has completed the study protocol.